One more infant sickened with botulism in outbreak tied to powdered formula
A promising investigational vaccine for Shigella bacteria has demonstrated high-level protection in a phase 2 clinical trial, as reported recently in The Lancet Infectious Diseases. The challenge trial, conducted at two U.S. sites, involved 73 healthy adults aged 18 to 49. Participants were randomly assigned to receive either WRS2, an oral live-attenuated vaccine targeting Shigella … Read more